This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Biogen Ma Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Matthew P. Scaramozza and Combination Treatment Methods for Multiple Sclerosis.
Introduction
Matthew P. Scaramozza is an inventor associated with West Roxbury, Massachusetts, and Biogen MA Inc. His patent work includes a proposed combination approach to treating autoimmune diseases, including multiple sclerosis.
Latest Patents
Scaramozza is credited with 1 patent, titled “Combination Treatment Methods of Multiple Sclerosis.” The disclosure describes administering a Bruton’s tyrosine kinase (BTK) inhibitor together with a fumaric acid ester (FAE) to treat an autoimmune disease. It identifies multiple sclerosis as one potential application and also lists lupus, rheumatoid arthritis, pemphigus vulgaris, neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, anti-NMDA receptor encephalitis, and Sjögren’s disease.
Career Highlights
The available information associates Scaramozza with Biogen MA Inc. and identifies his patent contribution in the field of combination therapies for autoimmune diseases. The patent disclosure focuses on combining two classes of therapeutic agents.
Collaborations
Catherine Barbey and Michael Christian Mingueneau are identified as Scaramozza’s coworkers. The provided information does not specify their roles in the patent or the details of any collaboration.
Conclusion
Matthew P. Scaramozza’s recorded patent contribution concerns a combination-treatment strategy for multiple sclerosis and other autoimmune diseases, reflecting research into potential therapeutic approaches.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile